Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2019-05-06
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare how well 2 different dosing schedules
of decitabine may help control AML.
Decitabine is designed to damage the DNA (the genetic material) of cells, which may cause
cancer cells to die.